Frazier Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
$60.7M Buy
2,772,062
+1,583,927
+133% +$29.3M 4.67% 4
2021
Q3
$22.7M Hold
1,188,135
– – 1.82% 17
2021
Q2
$20.4M Sell
1,188,135
-246,910
-17% -$4.52M 1.88% 13
2021
Q1
$32.1M Buy
1,435,045
+30,000
+2% +$678K 2.57% 11
2020
Q4
$31.2M Buy
1,405,045
+85,000
+6% +$1.76M 2.41% 12
2020
Q3
$19.5M Hold
1,320,045
– – 1.75% 13
2020
Q2
$19.6M Buy
1,320,045
+329,334
+33% +$5.02M 1.72% 13
2020
Q1
$10.9M Buy
+990,711
New +$9.3M 1.23% 12

Other funds holding SNDX

Frazier Management's SNDX Position: Q4 2021 in Review

Frazier Management increased its Syndax Pharmaceuticals (SNDX) stake by 133% in Q4 2021, buying an estimated $29.3M and bringing the position to 2,772,062 shares worth $60.7M. The position accounts for 4.67% of the portfolio, ranked #4.

Frazier Management first reported a position in SNDX in Q1 2020 and has held it in 8 quarters since. 132 funds tracked by Wall St. Rank hold SNDX as of Q4 2021.

  • Frazier Management held 2,772,062 shares of Syndax Pharmaceuticals worth $60.7M as of Q4 2021.
  • Frazier Management bought 1,583,927 Syndax Pharmaceuticals shares in Q4 2021, an estimated $29.3M.
  • Syndax Pharmaceuticals made up 4.67% of Frazier Management's portfolio in Q4 2021, its #4 holding.
  • Frazier Management first reported a position in Syndax Pharmaceuticals in Q1 2020 and has held it in 8 quarters since.
  • 132 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2021.

Based on Frazier Management's 13F filing for Q4 2021, filed 8 Feb 2022.